Benzinga | Jan 8, 2021 11:06AM EST

Raymond James Maintains Strong Buy on NGM Biopharmaceuticals, Raises Price Target to $50

Raymond James maintains NGM Biopharmaceuticals (NASDAQ:NGM) with a Strong Buy and raises the price target from $32 to $50.